Wall Street brokerages forecast that Sorrento Therapeutics, Inc. (NASDAQ:SRNE – Get Rating) will announce $17.83 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Sorrento Therapeutics’ earnings. The lowest sales estimate is $14.54 million and the highest is $21.12 million. Sorrento Therapeutics reported sales of $14.26 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 25%. The company is expected to issue its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Sorrento Therapeutics will report full-year sales of $106.17 million for the current fiscal year, with estimates ranging from $75.78 million to $136.55 million. For the next fiscal year, analysts expect that the business will post sales of $5.10 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for Sorrento Therapeutics.
A number of equities research analysts have recently commented on the company. StockNews.com cut Sorrento Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Zacks Investment Research upgraded Sorrento Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, HC Wainwright dropped their target price on Sorrento Therapeutics from $26.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, March 25th.
Shares of NASDAQ:SRNE traded up $0.01 during trading on Monday, reaching $1.59. 5,161,518 shares of the company’s stock traded hands, compared to its average volume of 10,216,579. Sorrento Therapeutics has a fifty-two week low of $1.15 and a fifty-two week high of $11.07. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.62 and a quick ratio of 1.18. The company has a 50-day simple moving average of $1.93 and a 200-day simple moving average of $3.62.
Sorrento Therapeutics Company Profile (Get Rating)
Sorrento Therapeutics, Inc, a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.
- Get a free copy of the StockNews.com research report on Sorrento Therapeutics (SRNE)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.